| Schedule of disaggregated revenue |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended September 30, | | | | Diagnostics | | | Therapeutic Devices | | | Development Services | | | Consolidated | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 | Capital | | $ | 161 | | $ | 188 | | $ | 1,829 | | $ | 2,007 | | $ | 18 | | $ | - | | $ | 2,008 | | $ | 2,195 | Consumables | | | 1,464 | | | 574 | | | 5,299 | | | 4,628 | | | 31 | | | 179 | | | 6,794 | | | 5,381 | Engineering | | | - | | | - | | | - | | | - | | | 981 | | | 483 | | | 981 | | | 483 | Other | | | - | | | - | | | 41 | | | 36 | | | 75 | | | - | | | 116 | | | 36 | Total revenue | | $ | 1,625 | | $ | 762 | | $ | 7,169 | | $ | 6,671 | | $ | 1,105 | | $ | 662 | | $ | 9,899 | | $ | 8,095 |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | Nine Months Ended September 30, | | | | Diagnostics | | | Therapeutic Devices | | | Development Services | | | Consolidated | | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 | | | 2026 | | | 2025 | Capital | | $ | 538 | | $ | 572 | | $ | 4,888 | | $ | 5,232 | | $ | 395 | | $ | - | | $ | 5,821 | | $ | 5,804 | Consumables | | | 3,438 | | | 1,530 | | | 14,780 | | | 13,461 | | | 695 | | | 179 | | | 18,913 | | | 15,170 | Engineering | | | - | | | - | | | - | | | - | | | 3,204 | | | 483 | | | 3,204 | | | 483 | Other | | | - | | | - | | | 76 | | | 102 | | | 196 | | | - | | | 272 | | | 102 | Total revenue | | $ | 3,976 | | $ | 2,102 | | $ | 19,744 | | $ | 18,795 | | $ | 4,490 | | $ | 662 | | $ | 28,210 | | $ | 21,559 |
|